Navigation Links
Debiopharm International SA and Arbor Pharmaceuticals, LLC Announce Their US Commercialization Partnership for Triptorelin in Central Precocious Puberty
Date:1/11/2016

LAUSANNE, Switzerland and ATLANTA, January 11, 2016 /PRNewswire/ --

Debiopharm International SA (Debiopharm), part of Debiopharm Group™, a Swiss-based global biopharmaceutical company, and Arbor Pharmaceuticals, LCC (Arbor), a U.S.-based specialty pharmaceutical company, jointly announce the execution of a distribution agreement for the commercialization and promotion of triptorelin 22.5 mg in the United States for central precocious puberty (CPP).

Under the terms of the agreement, Arbor acquires exclusive commercial rights for triptorelin 22.5 mg in the U.S., for the CPP indication. The product will be exported from Debiopharm Research and Manufacturing SA to Arbor. Once approved, triptorelin 22.5 mg will be made available primarily to pediatricians and pediatric endocrinologists.

"We are delighted to be partnering with an excellent research based company like Debiopharm to bring this important product to pediatric patients in the United States," said Ed Schutter, President and CEO of Arbor. "We are looking forward to working with them to file this unique dosage form of sustained-release triptorelin with the FDA in the near future."

"We are happy to have found a good partner to commercialize our product in this orphan indication," said Thierry Mauvernay, Co-President & Delegate of the Board of Debiopharm Group. "It is important to us to make this treatment option with its 6-monthly administration available to these young patients."

About Central Precocious Puberty (CPP)  

GnRH-dependent CPP is defined by pubertal development occurring before the age of 8 years in girls and 9 years in boys. It is characterized by early pubertal changes such as breast development and start of menses in girls and increased testicular and penile growth in boys, appearance of pubic hair, as well as acceleration of growth velocity and bone maturation, which often results in reduced adult height and disproportioned body appearance due to premature fusion of the growth plates. Reliable epidemiological data on CPP worldwide are not available. The condition occurs in about 1 out of every 5,000 to 10,000 children (leading to an estimated prevalence of 10,000 to 20,000 children in the USA). These numbers show that CPP is a rare disease. Central precocious puberty is more common in girls than in boys, with a female: male ratio estimated to be between 3:1 and 23:1.

About Triptorelin  

Triptorelin is an agonist analogue of the natural gonadotropin-releasing hormone (GnRH). Debiopharm has developed three sustained-release formulations (1, 3 and 6 months) of triptorelin pamoate. The 1-, 3- and 6-month formulations have been registered in numerous countries in several indications.

About Debiopharm International SA  

Debiopharm Group is a Swiss-based global biopharmaceutical group of four companies active in drug development, GMP manufacturing of proprietary drugs, diagnostics, and investment management. Debiopharm International SA is focused on the development of prescription drugs that target unmet medical needs. The company in-licenses and develops promising drug candidates. The products are commercialized by pharmaceutical out-licensing partners to give access to the largest number of patients worldwide.

For more information, please visit http://www.debiopharm.com

We are on Twitter. Follow us @DebiopharmNews at http://twitter.com/DebiopharmNews

About Arbor Pharmaceuticals, LLC  

Arbor Pharmaceuticals, headquartered in Atlanta, Georgia, is a specialty pharmaceutical company currently focused on the cardiovascular, hospital and pediatric markets as well as generics through its Wilshire division. The company has approximately 600 employees, with over 500 sales professionals that promote its products to hospitals and physicians. In addition to its extensive pipeline, the company continues to actively pursue growth through acquisition or licensing of marketed or late-stage development products. Arbor currently markets eighteen approved NDA and ANDA products, and, along with Wilshire, has over forty products in development. For more information regarding Arbor Pharmaceuticals or any of its products, visit http://www.arborpharma.com or send email inquiries to info@arborpharma.com

Debiopharm International SA Contact
Christelle Tur
Communication Coordinator
christelle.tur@debiopharm.com
Tel: +41(0)21-321-01-11

Arbor Pharmaceuticals, LLC Contact
Jason McCarthy
CFO
jmccarthy@arborpharma.com
Tel: +1-678-334-2423

Additional Media Contacts
In London
Maitland
Chiara Valsangiacomo
cvalsangiacomo@maitland.co.uk
Tel: +44(0)20-7379-5151

In New York
Russo Partners, LLC
Lena Evans
Assistant Vice President
lena.evans@russopartnersllc.com
Tel: +1-212-845-4262

 


'/>"/>
SOURCE Debiopharm Group
Copyright©2016 PR Newswire.
All rights reserved


Related biology technology :

1. Debiopharm International SA Presents Positive Preliminary Results From Phase 1 Trials in the Development of the IAP Inhibitor Debio 1143 at the 27th EORTC-NCI-AACR Symposium in Boston
2. Debiopharm International SA und Solid Biosciences, LLC, kündigen Partnerschaft an, um die Anwendung von Alisporivir (Debio 025) bei Muskeldystrophie zu erforschen
3. Debiopharm International SA Announces Results of 2 Key Oncology Programs at 2015 AACR Conference
4. Oncotest GmbH and Debiopharm Group Announce a Successful Partnership in the Identification of Biomarker Candidates
5. Xcovery Announces Updated Clinical Data on X-396 in Patients with ALK+ Non-Small Cell Lung Cancer at the 4th AACR-IASLC International Joint Conference
6. VetStem Biopharma, Inc. Founder and CEO, Dr. Robert Harman, to Speak at the International Canine Sports Medicine Symposium
7. Huya Bioscience International Announces Orphan Drug Designation For HBI-8000 In Japan
8. SFI International Recognized for Adopting Bacopa through American Botanical Councils Adopt-an-Herb Program
9. Pharnext beginnt PLEO-CMT, eine internationale Phase-III-Zulassungsstudie bei Charcot-Marie-Tooth-Krankheit Typ 1A
10. Pharnext Initiates PLEO-CMT, an International Pivotal Phase 3 Trial, in Charcot-Marie-Tooth disease type 1A
11. HUYA Bioscience International Expands Senior Management Team
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2019)... ... September 30, 2019 , ... ... newsletter from Rigaku Corporation , is now available online on the company’s ... based materials science, including X-ray diffraction, fluorescence and imaging, and presents articles, scientific ...
(Date:9/24/2019)... ... 24, 2019 , ... Drug resistance has been declared as one of the ... becoming one of the most serious concerns. Hong Kong cannot be spared from the ... (CA-MRSA), or a seven-fold of the figure in 2007 – the year the disease ...
(Date:9/24/2019)... ... September 24, 2019 , ... Personalized Stem Cells, ... site qualification for clinical trial sites and physician investigators. The clinical trial ... trial participants. , Clinical trial sites are currently located in San Diego and ...
(Date:9/24/2019)... ... September 24, 2019 , ... In the past three years, the National ... at South Dakota School of Mines & Technology that expands human understanding ... surfaces to form a slimy and yet strong layer which is commonly known as ...
Breaking Biology Technology:
(Date:10/10/2019)... ... October 09, 2019 , ... Calcium ... at Executive Plaza Hotel in Vancouver, Canada on September 23-24 for two days. ... various measures to develop healthy bone and to prevent calcium-related diseases. The theme ...
(Date:10/8/2019)... ... October 08, 2019 , ... Enplug , a leading ... than ever for businesses and organizations to use their digital signage networks to ... count down to or count up from date-related milestones, while the Holidays App ...
(Date:10/4/2019)... , ... October 04, 2019 , ... ... will be held November 10 at the Grand Elysée Hamburg Rothenbaumchaussee in Hamburg. ... Europe again this November,” said Miao Guo, Vice President of Operations and spokesperson ...
Breaking Biology News(10 mins):